Research graph
References from Efficacy, Tolerability, and Safety of Fluoxetine for Panic Disorder in Adults: A Review. Local targets link to admitted publications; unresolved targets remain external evidence.
Antidepressants versus placebo for panic disorder in adults
10.1002/14651858.cd010676.pub2 · 2018 · External reference
Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group
10.1176/ajp.155.11.1570 · 1998 · External reference
Generalised Anxiety Disorder and Panic Disorder in Adults: Management. NICE Clinical Guidelines, No. 113
2019 · External reference
Pharmacotherapy of panic disorder
10.2147/ndt.s1224 · 2008 · External reference
Is it possible to prevent relapse in panic disorder?
10.1080/14737175.2023.2229955 · 2023 · External reference
Pharmacological therapy in panic disorder: current guidelines and novel drugs discovery for treatment-resistant patient
10.9758/cpn.2019.17.2.145 · 2019 · External reference
Fluoxetine: a review on evidence based medicine
10.1186/1475-2832-3-2 · 2004 · External reference
Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial
10.1192/bjp.179.6.514 · 2001 · External reference
An open trial of fluoxetine in the treatment of panic attacks
10.1097/00004714-198710000-00007 · 1987 · External reference
Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramine and paroxetine binding study
1995 · External reference
Impact of CYP2D6 genotype on fluoxetine exposure and treatment switch in adults and children/adolescents
10.1007/s00228-025-03893-9 · 2025 · External reference
Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids
10.1021/ja048114o · 2004 · External reference
Pharmacogenomics of CYP2D6, CYP2C19, CYP2C9, and clinical determinants of fluoxetine-norfluoxetine pharmacokinetics in real-world clinical conditions
10.3390/pharmaceutics18010041 · 2025 · External reference
Hydrochloride salt co-crystals: preparation, characterization and physicochemical studies
10.3109/10837450.2012.696270 · 2013 · External reference
Potentiation of brain bioavailability using thermoreversible cubosomal formulation
10.1021/acs.molpharmaceut.4c00085 · 2024 · External reference
PEGylated chitosan nanoparticles of fluoxetine enhance cognitive performance and hippocampal brain derived neurotrophic factor levels in a rat model of local demyelination
10.1016/j.exger.2024.112533 · 2024 · External reference
Newer antidepressants and panic disorder: a meta-analysis
10.1097/yic.0b013e32835a5d2e · 2013 · External reference
Comparative efficacy and acceptability of antidepressants and benzodiazepines for the treatment of panic disorder: a systematic review and network meta-analysis
10.1016/j.ajp.2021.102664 · 2021 · External reference
Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials
10.1136/bmj-2021-066084 · 2022 · External reference
Pharmacological treatments in panic disorder in adults: a network meta-analysis
10.1002/14651858.cd012729.pub3 · 2023 · External reference
Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group
10.1007/pl00014164 · 1999 · External reference
Mirtazapine versus fluoxetine in the treatment of panic disorder
10.1590/s0100-879x2001001000010 · 2001 · External reference
The assessment of anxiety states by rating
10.1111/j.2044-8341.1959.tb00467.x · 1959 · External reference
The Anxiety Disease
1983 · External reference
Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder
10.4088/jcp.v60n0505 · 1999 · External reference
Is the efficacy of antidepressants in panic disorder mediated by adverse events? A mediational analysis
10.1371/journal.pone.0178617 · 2017 · External reference
Antidepressant withdrawal and rebound phenomena
10.3238/arztebl.2019.0355 · 2019 · External reference
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants
10.1002/cpt.2903 · 2023 · External reference
Fluoxetine
2026 · External reference
Is a combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia
10.1111/j.1600-0447.2008.01157.x · 2008 · External reference
Innovative virtual reality exposure therapy for anxiety and posttraumatic stress disorder: a meta-analysis of randomised controlled trials
10.7189/jogh.16.04090 · 2026 · External reference
Pilot randomized trial of self-guided virtual reality exposure therapy for social anxiety disorder
10.1016/j.brat.2021.103984 · 2021 · External reference
Personalized virtual reality exposure for panic disorder and agoraphobia: a preliminary neurophysiological study
10.1016/j.comppsych.2023.152447 · 2024 · External reference
Self-efficacy: toward a unifying theory of behavioral change
10.1037/0033-295x.84.2.191 · 1977 · External reference
Mechanisms of change in cognitive behavioral therapy for panic disorder: the unique effects of self-efficacy and anxiety sensitivity
10.1016/j.brat.2013.09.001 · 2013 · External reference
Antidepressants versus placebo for panic disorder in adults
10.1002/14651858.cd010676.pub2 · ExternalCitation · doi-reference
Pharmacological treatments in panic disorder in adults: a network meta-analysis
10.1002/14651858.cd012729.pub3 · ExternalCitation · doi-reference
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants
10.1002/cpt.2903 · ExternalCitation · doi-reference
Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group
10.1007/pl00014164 · ExternalCitation · doi-reference
Impact of CYP2D6 genotype on fluoxetine exposure and treatment switch in adults and children/adolescents
10.1007/s00228-025-03893-9 · ExternalCitation · doi-reference
Comparative efficacy and acceptability of antidepressants and benzodiazepines for the treatment of panic disorder: a systematic review and network meta-analysis
10.1016/j.ajp.2021.102664 · ExternalCitation · doi-reference
Mechanisms of change in cognitive behavioral therapy for panic disorder: the unique effects of self-efficacy and anxiety sensitivity
10.1016/j.brat.2013.09.001 · ExternalCitation · doi-reference
Pilot randomized trial of self-guided virtual reality exposure therapy for social anxiety disorder
10.1016/j.brat.2021.103984 · ExternalCitation · doi-reference
Personalized virtual reality exposure for panic disorder and agoraphobia: a preliminary neurophysiological study
10.1016/j.comppsych.2023.152447 · ExternalCitation · doi-reference
PEGylated chitosan nanoparticles of fluoxetine enhance cognitive performance and hippocampal brain derived neurotrophic factor levels in a rat model of local demyelination
10.1016/j.exger.2024.112533 · ExternalCitation · doi-reference
Potentiation of brain bioavailability using thermoreversible cubosomal formulation
10.1021/acs.molpharmaceut.4c00085 · ExternalCitation · doi-reference
Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids
10.1021/ja048114o · ExternalCitation · doi-reference
Self-efficacy: toward a unifying theory of behavioral change
10.1037/0033-295x.84.2.191 · ExternalCitation · doi-reference
Is it possible to prevent relapse in panic disorder?
10.1080/14737175.2023.2229955 · ExternalCitation · doi-reference
An open trial of fluoxetine in the treatment of panic attacks
10.1097/00004714-198710000-00007 · ExternalCitation · doi-reference
Newer antidepressants and panic disorder: a meta-analysis
10.1097/yic.0b013e32835a5d2e · ExternalCitation · doi-reference
Is a combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia
10.1111/j.1600-0447.2008.01157.x · ExternalCitation · doi-reference
The assessment of anxiety states by rating
10.1111/j.2044-8341.1959.tb00467.x · ExternalCitation · doi-reference
Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials
10.1136/bmj-2021-066084 · ExternalCitation · doi-reference
Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group
10.1176/ajp.155.11.1570 · ExternalCitation · doi-reference
Fluoxetine: a review on evidence based medicine
10.1186/1475-2832-3-2 · ExternalCitation · doi-reference
Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial
10.1192/bjp.179.6.514 · ExternalCitation · doi-reference
Is the efficacy of antidepressants in panic disorder mediated by adverse events? A mediational analysis
10.1371/journal.pone.0178617 · ExternalCitation · doi-reference
Mirtazapine versus fluoxetine in the treatment of panic disorder
10.1590/s0100-879x2001001000010 · ExternalCitation · doi-reference
Pharmacotherapy of panic disorder
10.2147/ndt.s1224 · ExternalCitation · doi-reference
Hydrochloride salt co-crystals: preparation, characterization and physicochemical studies
10.3109/10837450.2012.696270 · ExternalCitation · doi-reference
Antidepressant withdrawal and rebound phenomena
10.3238/arztebl.2019.0355 · ExternalCitation · doi-reference
Pharmacogenomics of CYP2D6, CYP2C19, CYP2C9, and clinical determinants of fluoxetine-norfluoxetine pharmacokinetics in real-world clinical conditions
10.3390/pharmaceutics18010041 · ExternalCitation · doi-reference
Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder
10.4088/jcp.v60n0505 · ExternalCitation · doi-reference
Innovative virtual reality exposure therapy for anxiety and posttraumatic stress disorder: a meta-analysis of randomised controlled trials
10.7189/jogh.16.04090 · ExternalCitation · doi-reference
Pharmacological therapy in panic disorder: current guidelines and novel drugs discovery for treatment-resistant patient
10.9758/cpn.2019.17.2.145 · ExternalCitation · doi-reference
